‘AML continues to be a disease with a significant unmet medical want and brand-new therapies are urgently needed,’ stated M. Scott Salka, CEO of Ambit Biosciences. ‘The Phase I medical data we’ve noticed for AC220 in AML are extremely encouraging and supports the further development of this highly selective second-generation FLT3 inhibitor.’ Related StoriesPenn research forms basis for fresh treatment approaches for Sezary syndromePotential new drug target for acute myeloid leukemiaDr. Paul Liu called 2015 Distinguished Alumnus for contributions to leukemia researchData Highlights for AC220 consist of: ORAL PRESENTATIONS Abstract #636 AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor, in a First-in-Human Stage 1 AML Study Provided by: Jorge Cortes, MD Program Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Time: Monday, 7 December, 2009, 5:45pm , Morial Convention Center Room 343-345 POSTER PRESENTATIONS Abstract# 2053 AC220 – A FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Types of Acute Myeloid Leukemia and Sustained Safety Following Chronic Administration Session Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Sunday, 6 December, 2009, 6:00 – 8:00pm, Hall E, Poster Board II-45 Abstract#: 2052 AC220, a Potent and Particular FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Lifestyle and in Mouse Tumor Xenograft Program Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Sunday, December 6, 2009, 6:00 PM – 8:00 PM, Hall E, Poster Board II-44..Net reduction for the entire year ended December 31, 2013 was $27.7 million, in comparison to a net lack of $19.december 31 2 million for the year ended, 2012. Cash, money equivalents and marketable securities had been $77.at December 31 4 million, 2013. Upcoming Occasions and Presentations People of BIND's management team are anticipated to create presentations at the next events: NASDAQ Starting Bell Ceremony in the NASDAQ MarketSite in Situations Square, NY in 9:30 a.m. On Wednesday ET, March 26, 2014.